SCHEMBL6103355

SCHEMBL6103355

Cn1cncc1-c1ccnc(Nc2ccc(S(N)(=O)=O)cc2)n1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 4/20 0.69
▸ IGF1R P08069 1/20 0.60
▸ IKBKB O14920 11/20 0.59
▸ DKK1 O94907 2/20 0.58
▸ GSK3B P49841 2/20 0.58
▸ MAPK8 P45983 1/20 0.57
▸ MAPK10 P53779 1/20 0.57
▸ CCNT1 O60563 3/20 0.56
▸ CDK1 P06493 3/20 0.56
▸ CCNB1 P14635 3/20 0.56
▸ CDK9 P50750 3/20 0.56
▸ CCNA2 P20248 1/20 0.56
▸ CDK7 P50613 1/20 0.56
▸ CCNH P51946 1/20 0.56
▸ CCNA1 P78396 1/20 0.56
▸ CDK4 P11802 1/20 0.53
▸ JAK2 O60674 1/20 0.52
▸ CHUK O15111 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6599115 0.83 CDK2 (0.58) CDK2IKBKBGSK3BMAPK8CCNT1
SCHEMBL6593229 0.83 IKBKB (0.61) CDK2IKBKBCDK1CDK4
SCHEMBL6596998 0.83 CDK2 (0.54) CDK2IKBKBGSK3BMAPK8CCNT1
SCHEMBL6104395 0.82 CDK2 (1.00) CDK2IGF1RIKBKBDKK1GSK3B
SCHEMBL6107380 0.82 CA2 (0.53) CDK2IKBKBCCNT1CDK1CCNB1
SCHEMBL6105366 0.82 PRKCD (0.57) CDK2IKBKBGSK3BMAPK10CDK1
SCHEMBL27536219 0.81 CDK2 (0.46) CDK2IGF1RGSK3BMAPK8MAPK10
SCHEMBL6598403 0.79 ABL1 (0.51) CDK2IKBKBGSK3BMAPK8CCNT1
SCHEMBL6295111 0.79 CDK2 (0.68) CDK2IKBKBCDK1CDK4
SCHEMBL27512174 0.79 CDK2 (0.49) CDK2CDK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB 2006-01-05 — — US disclosed
US-6969714-B2 Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation ASTRAZENECA AB (SE) 2005-11-29 — — US disclosed
EP-1351958-B1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2004-06-16 — — EP disclosed
WO-2002020512-A9 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2004-05-06 — — WO disclosed
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration ASTRAZENECA AB (SE) 2004-01-22 — — US disclosed
EP-1351958-A1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION AstraZeneca AB (SE) 2003-10-15 — — EP disclosed
WO-2002020512-A1 IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION ASTRAZENECA AB (SE) 2002-03-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004033-A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation MKI67, CCNI, CCNT1 CDK2 13/4885IGF1R 199/4885IKBKB 386/4885
US-20040014776-A1 Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration CCNI, TYMP, MKI67 CDK2 11/4885IGF1R 326/4885IKBKB 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback